The Royal Oldham Hospital has become the latest NHS facility to adopt Creo Medical Group PLC's (AIM:CREO) Speedboat Inject technology.
Surgeons there will use the breakthrough device in endoscopy rooms, marking a critical advance in bowel cancer treatment.
Creo noted the hospital's swift integration following extensive training under the company's Pioneer clinical education and mentoring programme.
The Royal Oldham, after ordering several of Creo's CROMA advanced energy platforms and Speedboat devices, has already implemented weekly schedules for Speedboat Submucosal Dissection (SSD) procedures.
A team of three doctors, trained through Creo's Pioneer Programme, successfully performed their inaugural SSD in late April. The endoscopy team has since handled over a dozen additional cases.
Creo Medical anticipates continued high usage from the trained physicians as they combat NHS waiting lists cost-effectively. SSD has already demonstrated cost savings of up to £10,000 per procedure compared to surgical alternatives, potentially benefiting hundreds of patients annually by providing less invasive options and reducing complications.
The Royal Oldham is the 23rd NHS operation to use SSD, with twelve now high-volume users. Creo conservatively estimates that over 350 UK hospitals could benefit from implementing Speedboat Inject and SSD.
Creo Medical CEO, Craig Gulliford, highlighted the Royal Oldham Hospital's swift adoption of Speedboat as a testament to the company's focus on training and mentoring. This aligns with the company's business strategy, particularly post-COVID, of establishing multiple services with their advanced energy platform and single-use devices to accelerate patient benefit and drive business growth.